High LDL-C Not Causally Linked to Risk for Retinopathy and Neuropathy
Investigators analyzed whether high LDL-C causally relates to risk for retinopathy, neuropathy, chronic kidney disease, and peripheral artery disease in the general population.
Dyslipidemia
Evolocumab Rapidly Reduces LDL-C When Added to High-Intensity Statin in ACS
Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.
World Trade Center Site Exposure Linked to Lasting CVD Risk
Greater exposure to the World Trade Center (WTC) site is associated with increased long-term cardiovascular disease risk.
Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial
Results demonstrated inclisiran to have met both primary end points with a favorable safety profile.
Higher Total Cholesterol and LDL-C Levels Associated With Lower WBC Count
There are modest associations between higher lipid levels and circulating leukocyte counts in humans.
Lomitapide Reduces LDL-C Levels in Homozygous Familial Hypercholesterolemia
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
Metabolic Syndrome and Cardiovascular Risk Management After Liver Transplantation
Significant improvements to the management of metabolic syndrome after liver transplantation must be made to reduce the risk for CV events and mortality.
Managing Hypertriglyceridemia With Omega-3 Fatty Acids: An AHA Advisory
The advisory from the American Heart Association aggregates the research performed thus far on the use of omega-3 fatty acids in hypertriglyceridemia and recommends a dose of 4 g/d to observe a therapeutic effect.
Revised AAP Hypertension Guidelines Identify Obese Youth With High CV Risk
A significant number of overweight and obese young people who are classified as nonhypertensive by the European Society of Hypertension criteria have high blood pressure and increased cardiovascular risk, according to newer American Academy of Pediatrics guidelines.
Low-Cost, Fixed-Dose Polypill Reduces Risk for Major CV Events
Use of a four-component polypill can effectively reduce the risk for major cardiovascular events.
Next post in News
